Erasca Reports Q4 2025 Financial Results with Reduced Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ERAS?
Source: seekingalpha
- Reduced Net Loss: Erasca reported a net loss of $29.1 million for Q4 2025, translating to a loss of $0.10 per share, which is an improvement from the $32.2 million loss and $0.11 per share in Q4 2024, indicating initial success in cost management efforts.
- Annual Loss Overview: For the full year 2025, the company recorded a net loss of $124.5 million, or $0.44 per share, a significant reduction from the $161.7 million loss and $0.69 per share in 2024, reflecting gradual improvements in financial health.
- Stock Offering Announcement: Erasca has priced a $225 million stock offering at $10 per share, aimed at strengthening its capital base to support future R&D and operational needs, demonstrating the company's confidence in the market.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest and highlighting its active presence in the industry along with future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 14.970
Low
2.00
Averages
5.50
High
11.00
Current: 14.970
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca CMO Sells Shares Under 10b5-1 Plan
- Transaction Overview: On March 4, 2026, Erasca's Chief Medical Officer, Morris Shannon, exercised and sold 20,000 shares of common stock for approximately $301,000 at an average price of $15.04 per share, reflecting routine compensation management for executives.
- Ownership Change Analysis: This transaction reduced Shannon's direct holdings to zero; however, this does not indicate a loss of investment in the company as she retains 515,800 options, ensuring continued exposure to Erasca's future.
- Trading Plan Context: The stock sale was executed under a pre-established 10b5-1 trading plan set in June 2024, indicating that the transaction was planned and compliant with corporate governance, mitigating market concerns regarding her ownership changes.
- Company Strategic Positioning: Erasca focuses on developing precision oncology therapeutics for RAS/MAPK pathway-driven cancers, leveraging a robust pipeline and deep expertise in molecular oncology to address significant unmet medical needs and enhance its competitive edge in the rapidly evolving oncology market.
See More
Erasca CMO Sells Shares in SEC Filing
- Transaction Overview: Morris Shannon, CMO of Erasca, reported the sale of 20,000 shares of common stock valued at approximately $301,000 in an SEC Form 4 filing, indicating a strategic liquidity management approach.
- Direct Ownership Change: Following this transaction, Shannon's direct common stock holdings dropped to zero; however, he retains rights to acquire up to 515,800 shares through stock options, highlighting significant future equity exposure.
- Market Reaction Analysis: The reduction of Shannon's direct holdings to zero does not imply pessimism about the company's outlook, but rather reflects routine compensation management under a pre-established 10b5-1 trading plan from June 2024, reinforcing confidence in Erasca's future.
- Company Background and Outlook: Erasca focuses on developing precision oncology therapeutics targeting the RAS/MAPK pathway, with future revenue expected from drug approvals and licensing agreements, achieving a market capitalization of $4.71 billion, showcasing its competitive edge in the rapidly evolving oncology market.
See More
Erasca Reports Q4 2025 Financial Results with Reduced Losses
- Reduced Net Loss: Erasca reported a net loss of $29.1 million for Q4 2025, translating to a loss of $0.10 per share, which is an improvement from the $32.2 million loss and $0.11 per share in Q4 2024, indicating initial success in cost management efforts.
- Annual Loss Overview: For the full year 2025, the company recorded a net loss of $124.5 million, or $0.44 per share, a significant reduction from the $161.7 million loss and $0.69 per share in 2024, reflecting gradual improvements in financial health.
- Stock Offering Announcement: Erasca has priced a $225 million stock offering at $10 per share, aimed at strengthening its capital base to support future R&D and operational needs, demonstrating the company's confidence in the market.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest and highlighting its active presence in the industry along with future growth potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- OKTA Stock Outlook: Analysts' perspectives on OKTA stock have garnered attention, prompting investors to consider these rating changes when contemplating purchases for more informed investment choices.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly affect stock prices, necessitating that investors closely monitor these changes to seize market opportunities.
- Comprehensive Analysis View: For a complete overview of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page for more detailed information and data.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
Erasca CMO Sells Shares Under 10b5-1 Plan
- Transaction Overview: On March 4, 2026, Erasca's Chief Medical Officer, Morris Shannon, exercised and sold 20,000 shares of common stock for approximately $301,000 at an average price of $15.04 per share, reflecting routine compensation management for executives.
- Ownership Change Analysis: This transaction reduced Shannon's direct holdings to zero; however, this does not indicate a loss of investment in the company as she retains 515,800 options, ensuring continued exposure to Erasca's future.
- Trading Plan Context: The stock sale was executed under a pre-established 10b5-1 trading plan set in June 2024, indicating that the transaction was planned and compliant with corporate governance, mitigating market concerns regarding her ownership changes.
- Company Strategic Positioning: Erasca focuses on developing precision oncology therapeutics for RAS/MAPK pathway-driven cancers, leveraging a robust pipeline and deep expertise in molecular oncology to address significant unmet medical needs and enhance its competitive edge in the rapidly evolving oncology market.
See More
Erasca CMO Sells Shares in SEC Filing
- Transaction Overview: Morris Shannon, CMO of Erasca, reported the sale of 20,000 shares of common stock valued at approximately $301,000 in an SEC Form 4 filing, indicating a strategic liquidity management approach.
- Direct Ownership Change: Following this transaction, Shannon's direct common stock holdings dropped to zero; however, he retains rights to acquire up to 515,800 shares through stock options, highlighting significant future equity exposure.
- Market Reaction Analysis: The reduction of Shannon's direct holdings to zero does not imply pessimism about the company's outlook, but rather reflects routine compensation management under a pre-established 10b5-1 trading plan from June 2024, reinforcing confidence in Erasca's future.
- Company Background and Outlook: Erasca focuses on developing precision oncology therapeutics targeting the RAS/MAPK pathway, with future revenue expected from drug approvals and licensing agreements, achieving a market capitalization of $4.71 billion, showcasing its competitive edge in the rapidly evolving oncology market.
See More
Erasca Reports Q4 2025 Financial Results with Reduced Losses
- Reduced Net Loss: Erasca reported a net loss of $29.1 million for Q4 2025, translating to a loss of $0.10 per share, which is an improvement from the $32.2 million loss and $0.11 per share in Q4 2024, indicating initial success in cost management efforts.
- Annual Loss Overview: For the full year 2025, the company recorded a net loss of $124.5 million, or $0.44 per share, a significant reduction from the $161.7 million loss and $0.69 per share in 2024, reflecting gradual improvements in financial health.
- Stock Offering Announcement: Erasca has priced a $225 million stock offering at $10 per share, aimed at strengthening its capital base to support future R&D and operational needs, demonstrating the company's confidence in the market.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest and highlighting its active presence in the industry along with future growth potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- OKTA Stock Outlook: Analysts' perspectives on OKTA stock have garnered attention, prompting investors to consider these rating changes when contemplating purchases for more informed investment choices.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly affect stock prices, necessitating that investors closely monitor these changes to seize market opportunities.
- Comprehensive Analysis View: For a complete overview of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page for more detailed information and data.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
